BLIS Technologies (NZSE:BLT) Debt-to-Revenue : 0.03 (As of Mar. 2024)

View and export this data going back to 2001. Start your Free Trial

What is BLIS Technologies Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

BLIS Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was NZ$0.18 Mil. BLIS Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was NZ$0.21 Mil. BLIS Technologies's annualized Revenue for the quarter that ended in Mar. 2024 was NZ$12.38 Mil. BLIS Technologies's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.03.

BLIS Technologies Debt-to-Revenue Historical Data

The historical data trend for BLIS Technologies's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BLIS Technologies Debt-to-Revenue Chart

BLIS Technologies Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Debt-to-Revenue

Get a 7-Day Free Trial

0.05

0.06

0.09

0.06

0.04

BLIS Technologies Semi-Annual Data
	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24
Debt-to-Revenue	Get a 7-Day Free Trial															0.07	0.07	0.06	0.06	0.03

Competitive Comparison of BLIS Technologies's Debt-to-Revenue

For the Biotechnology subindustry, BLIS Technologies's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BLIS Technologies's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BLIS Technologies's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where BLIS Technologies's Debt-to-Revenue falls into.

BLIS Technologies Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

BLIS Technologies's Debt-to-Revenue for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.177	+	0.212)	/	10.484
	=	0.04

BLIS Technologies's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.177	+	0.212)	/	12.38
	=	0.03

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Mar. 2024) Revenue data.

BLIS Technologies Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of BLIS Technologies's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

BLIS Technologies (NZSE:BLT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BLIS Technologies Ltd (NZSE:BLT) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

442 Moray Place, Ground Floor, Dunedin, OTA, NZL, 9016

Website

https://www.blis.co.nz

BLIS Technologies Ltd is engaged in developing oral probiotics. The company markets two strains of probiotic bacteria BLIS K12, BLIS Q24, and BLIS M18 both of which occur naturally in the oral cavity. Its product portfolio consists of probiotic serum, Teeth and gums lozenge, fresh breath lozenge, and immune lozenge. Geographically, the company derives a majority of its revenue from EMEA (Europe, the Middle East, and Africa).